Introduction: The aim of this study was to investigate the characteristics of patients who were incidentally diagnosed with transitional cell carcinoma (TCC) during percutaneous nephrolithotomy (PCNL) surgery. Patients and Methods: We retrospectively analyzed the data of 1,406 patients who underwent PCNL for the removal of renal calculi. Tumoral lesions detected during diagnostic cystourethroscopy and nephroscopy were endoscopically resected and the resected specimens were sent to the pathology laboratory for definitive diagnosis. Results: Tumoral lesions were detected with cystoscopic examination in 6 patients and with nephroscopy in 4. Pathological examination of the lesions in the kidneys revealed stage T1G1 TCC in 2 patients, T1G3 TCC with carcinoma in situ in 1, and high-grade TCC with sarcomatoid features in 1 patient. The patient with sarcomatoid features died 2 months after surgery and all the other patients survived with no evidence of disease at the end of 26.67 ± 18.58 months of follow-up. Conclusions: Since early diagnosis and management of urothelial lesions significantly improves the prognosis, a careful examination of urothelial mucosa during PCNL surgery is important. Instant diagnosis of a sarcomatoid component and imperative surgical intervention may be life-saving.

Keywords:
Carcinoma, Percutaneous nephrolithotomy, Transitional cell, Transitional cell carcinoma, incidental findings
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.